In utero resolution of microcystic congenital cystic adenomatoid malformation after prenatal betamethasone therapy: A report of three cases and a literature review

Akiko Yamashita; Nobuhiro Hidaka; Ryo Yamamoto; Soichiro Nakayama; Jun Sasahara; Keisuke Ishii; Nobuaki Mitsuda

doi:10.1002/jcu.22214

In utero resolution of microcystic congenital cystic adenomatoid malformation after prenatal betamethasone therapy: A report of three cases and a literature review

Akiko Yamashita, Nobuhiro Hidaka, Ryo Yamamoto, Soichiro Nakayama, Jun Sasahara, Keisuke Ishii, Nobuaki Mitsuda

Comprehensive Maternity and Perinatal Care Center

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

Fetal congenital cystic adenomatoid malformation (CCAM) can progress to nonimmune hydrops, and the mortality rate of CCAM with hydrops is reported to be nearly 100%. We describe three microcystic CCAM cases in which the fetal condition improved after maternal betamethasone therapy. The median gestational age at steroid administration was 23 5/7 weeks' gestation. The CCAM decreased in size in all cases. Our series showed a 100% hydrops resolution rate (2/2) and a 100% survival rate (3/3). Our experience suggests the efficacy of betamethasone treatment on fetuses with microcystic CCAM who have fluid collection or are at risk of developing hydrops.

Original language	English
Pages (from-to)	451-457
Number of pages	7
Journal	Journal of Clinical Ultrasound
Volume	43
Issue number	7
DOIs	https://doi.org/10.1002/jcu.22214
Publication status	Published - Sept 2015

All Science Journal Classification (ASJC) codes

Radiology Nuclear Medicine and imaging

Access to Document

10.1002/jcu.22214

Cite this

@article{4dd83a4de9a54894ac90a4c23d16a634,

title = "In utero resolution of microcystic congenital cystic adenomatoid malformation after prenatal betamethasone therapy: A report of three cases and a literature review",

abstract = "Fetal congenital cystic adenomatoid malformation (CCAM) can progress to nonimmune hydrops, and the mortality rate of CCAM with hydrops is reported to be nearly 100%. We describe three microcystic CCAM cases in which the fetal condition improved after maternal betamethasone therapy. The median gestational age at steroid administration was 23 5/7 weeks' gestation. The CCAM decreased in size in all cases. Our series showed a 100% hydrops resolution rate (2/2) and a 100% survival rate (3/3). Our experience suggests the efficacy of betamethasone treatment on fetuses with microcystic CCAM who have fluid collection or are at risk of developing hydrops.",

author = "Akiko Yamashita and Nobuhiro Hidaka and Ryo Yamamoto and Soichiro Nakayama and Jun Sasahara and Keisuke Ishii and Nobuaki Mitsuda",

note = "Publisher Copyright: {\textcopyright} 2014 Wiley Periodicals, Inc.",

year = "2015",

month = sep,

doi = "10.1002/jcu.22214",

language = "English",

volume = "43",

pages = "451--457",

journal = "Journal of Clinical Ultrasound",

issn = "0091-2751",

publisher = "John Wiley and Sons Inc.",

number = "7",

}

TY - JOUR

T1 - In utero resolution of microcystic congenital cystic adenomatoid malformation after prenatal betamethasone therapy

T2 - A report of three cases and a literature review

AU - Yamashita, Akiko

AU - Hidaka, Nobuhiro

AU - Yamamoto, Ryo

AU - Nakayama, Soichiro

AU - Sasahara, Jun

AU - Ishii, Keisuke

AU - Mitsuda, Nobuaki

PY - 2015/9

Y1 - 2015/9

N2 - Fetal congenital cystic adenomatoid malformation (CCAM) can progress to nonimmune hydrops, and the mortality rate of CCAM with hydrops is reported to be nearly 100%. We describe three microcystic CCAM cases in which the fetal condition improved after maternal betamethasone therapy. The median gestational age at steroid administration was 23 5/7 weeks' gestation. The CCAM decreased in size in all cases. Our series showed a 100% hydrops resolution rate (2/2) and a 100% survival rate (3/3). Our experience suggests the efficacy of betamethasone treatment on fetuses with microcystic CCAM who have fluid collection or are at risk of developing hydrops.

AB - Fetal congenital cystic adenomatoid malformation (CCAM) can progress to nonimmune hydrops, and the mortality rate of CCAM with hydrops is reported to be nearly 100%. We describe three microcystic CCAM cases in which the fetal condition improved after maternal betamethasone therapy. The median gestational age at steroid administration was 23 5/7 weeks' gestation. The CCAM decreased in size in all cases. Our series showed a 100% hydrops resolution rate (2/2) and a 100% survival rate (3/3). Our experience suggests the efficacy of betamethasone treatment on fetuses with microcystic CCAM who have fluid collection or are at risk of developing hydrops.

UR - http://www.scopus.com/inward/record.url?scp=84948382822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948382822&partnerID=8YFLogxK

U2 - 10.1002/jcu.22214

DO - 10.1002/jcu.22214

M3 - Article

C2 - 25042751

AN - SCOPUS:84948382822

SN - 0091-2751

VL - 43

SP - 451

EP - 457

JO - Journal of Clinical Ultrasound

JF - Journal of Clinical Ultrasound

IS - 7

ER -

In utero resolution of microcystic congenital cystic adenomatoid malformation after prenatal betamethasone therapy: A report of three cases and a literature review

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this